Procept BioRobotics price target lowered to $30 from $47 at Truist

Truist lowered the firm’s price target on Procept BioRobotics (PRCT) to $30 from $47 but keeps a Buy rating on the shares. The company’s Q4 missed estimates, though its Analyst Day laid out a case for sustainable growth of 25% or more through 2027, highlighted by ongoing penetration into the BPH opportunity, strategy changes geared towards increasing utilization and more visibility into the business, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real- ...